549. MoCA Utility as a Quick Testing Tool for Neurocognitive Disorders in HIV Patients: Analysis of a Prospective Cohort
Session: Poster Abstract Session: HIV and Central Nervous System
Thursday, October 5, 2017
Room: Poster Hall CD
  • id week.pdf (592.3 kB)
  • Background: Since the introduction of highly active antiretroviral therapy, asymptomatic and mild neurocognitive impairment are the main clinical manifiestations of HIV associated neurocognitive disorders (HAND), compromising adherence to treatment, daily performance, quality of life, and even increasing the risk of mortality. We do not have validated screening tools for early detection of HAND applicable to the routine medical visit. The Montreal Cognitive Assessment test (MoCA) is a simple questionnaire used in Alzheimer's disease, but its utility as a screening tool for HAND remains controversial.

    Methods: We designed a prospective study to establish MoCA´s usefulness as a rapid and sensitive tool for the detection of HAND, compared to a gold-standard test (GST) that includes Mini-mental State Examination (MMSE) and a battery of assays that evaluate several neurological domains. Adult patients with HIV infection attending our institution were included. The MoCA test was performed by infectious diseases specialists, and the GST by neurologists. History of recent stroke, neurological disease, opportunistic central nervous system infection, major depression, schizophrenia, bipolar disorder, substance abuse or dependence on alcohol, were exclusion criteria. We analized demographic and clinical variables. 

    ResultsFifty HIV-infected patients were enrolled, 94% males, with a mean age of 45.6 years (range 20-75), and an average of 14.8 years of education (range 3-26). The mean CD4 cell count was 596 cells/ml (range 65-1130), and 70% of the patients had undetectable viral load (≤20 copies/ml) at the time of the evaluation. Compared to GST, MoCA had a sensibility (S) of 94.12% (CI 71.3-99.8), specificity (E) 78.79% (CI 61.09-91.02), Positive Predictive Value (PPV) 69.57% (CI 47-86.79) and Negative Predictive Value (NPV) 96.3 (CI 81-99.9). In contrast, the MMSE presented S 11.76% (CI 1.46-36.44), E 100% (CI 89.4-100), PPV 100% (CI 15.8-100) and NPV 68.75% (CI 53.7-81.3). Cohen's Kappa Coefficient between MoCA and GST was 0.67 (95% CI 0.46-0.87), reflecting an adequate agreement.

    ConclusionMoCA´s performance as a screening test was adequate compared to GST and far superior to MMSE for early detection of HAND. Although specifity could be optimized, MoCA test remains a valuable screening tool in the routine medical visit in our HIV population.

    Vanina Stanek, MD1, Marisa Del Luján Sanchez, MD1, Mariana De Paz Sierra, MD1, Cecilia Losada, MD1, Ines Zerboni, BSc(Psych)2, Maria Antonieta Gomez, BSc(Psych)2, Maria Mercedes Cegarra, BSc(Psych)2, María Cecilia Fernandez, MD2, Angel Golimstok, MD3 and Waldo Belloso, MD4, (1)Internal Medicine, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina, (2)Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina, (3)Neurology, Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina, (4)Fundacion IBIS CICAL, Buenos Aires, Argentina


    V. Stanek, None

    M. D. L. Sanchez, None

    M. De Paz Sierra, None

    C. Losada, None

    I. Zerboni, None

    M. A. Gomez, None

    M. M. Cegarra, None

    M. C. Fernandez, None

    A. Golimstok, None

    W. Belloso, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.